English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome

Gerasch, S., Kanaan, A. S., Jakubovski, E., & Müller-Vahl, K. (2016). Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Frontiers in Neuroscience, 10: 416. doi:10.3389/fnins.2016.00416.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-002B-5353-4 Version Permalink: http://hdl.handle.net/21.11116/0000-0003-1E8E-D
Genre: Journal Article

Files

show Files
hide Files
:
fnins-10-00416(1).pdf (Publisher version), 2MB
Name:
fnins-10-00416(1).pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Gerasch, Sarah1, Author
Kanaan, Ahmad S.1, 2, Author              
Jakubovski, Ewgeni1, Author
Müller-Vahl, Kirsten1, Author
Affiliations:
1Department of Psychiatry, Social psychiatry and Psychotherapy, Hannover Medical School MHH, Germany, ou_persistent22              
2Methods and Development Unit Nuclear Magnetic Resonance, MPI for Human Cognitive and Brain Sciences, Max Planck Society, Leipzig, DE, ou_634558              

Content

show
hide
Free keywords: Tourette Syndrome; Aripiprazole; OCD; Depression; Anxiety; ADHD; Premonitory urge; Quality of life
 Abstract: Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4–6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics in patients with GTS. It can be hypothesized that these beneficial effects are related to aripiprazole's adaptive pharmacological profile, which exhibits an influence on the dopaminergic as well as a number of other neurotransmitter systems. For the first time, our data provide evidence that patients' decision making process for or against medical treatment is influenced by other factors than tic severity and QoL.

Details

show
hide
Language(s): eng - English
 Dates: 2016-03-302016-08-262016-09-12
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.3389/fnins.2016.00416
PMID: 27672358
PMC: PMC5018494
Other: eCollection 2016
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Frontiers in Neuroscience
  Other : Front Neurosci
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 10 Sequence Number: 416 Start / End Page: - Identifier: ISSN: 1662-4548
ISSN: 1662-453X
CoNE: https://pure.mpg.de/cone/journals/resource/1662-4548